HER2-NEGATIVE BREAST CARCINOMA

This study tests a new drug called OP-1250 (palazestrant) against standard treatments (fulvestrant or an aromatase inhibitor) in 510 people with a common type of advanced breast cancer (ER+, HER2-). Participants must have already tried hormone therapy plus a CDK4/6 inhibitor. The…

This study tests a new drug, palazestrant, combined with ribociclib against the standard letrozole with ribociclib for people with ER+, HER2- advanced breast cancer that has not been treated before. About 1,000 adults with locally advanced or metastatic breast cancer will take pa…

This study tests whether adding an immunotherapy drug (durvalumab) to standard chemotherapy can prevent breast cancer from coming back in people with a high-risk form of hormone receptor-positive, HER2-negative breast cancer. About 3,680 adults with stage II or III breast cancer …

This study is for people with operable, lymph node-positive triple negative breast cancer. It tests whether adding low or high dose radiation to standard chemo and immunotherapy before surgery can improve outcomes. Participants receive radiation to the breast tumor over 3 days, t…

This early-stage trial is testing a new treatment for people with metastatic pancreatic or breast cancer that has spread. The treatment combines chemotherapy drugs with high-dose vitamin C and the patient's own stem cells to try to overcome drug resistance. The main goal is to ch…

This study tests different doses of the drug abemaciclib given together with radiation therapy for people with advanced hormone receptor-positive, HER2-negative breast cancer that has spread to the bone. The goal is to find the safest dose of abemaciclib when used alongside stand…

This study tests whether turkey tail mushrooms can help treat a common type of breast cancer in post-menopausal women. About 40 women will take the mushroom supplement in the weeks between diagnosis and surgery. Researchers will measure changes in a tumor growth marker (Ki-67) an…

This study looks at whether giving hormone therapy before surgery can lower the chance of cancer cells being found at the edges of removed tissue in women with stage 2 to 3 invasive lobular breast cancer. About 176 postmenopausal women with ER+/HER2- tumors will receive neoadjuva…

This study tests a system called CONCURxP that uses a special medication bag (WiseBag) and text message reminders to help people with metastatic breast cancer take their CDK4/6 inhibitor pills correctly. About 410 patients will either use the bag alone or the bag plus text remind…

This study tests whether a 10-week stress reduction program is practical and helpful for people with triple negative breast cancer. The program teaches relaxation, coping skills, and communication, and also connects participants with social services for needs like transportation …

This study looks at whether a lower dose of the chemotherapy drugs docetaxel and cyclophosphamide can effectively treat early-stage breast cancer in women aged 65 and older. Standard doses often cause harsh side effects in older patients. The goal is to find a dose that works wel…

This study tests whether in-person acupuncture or virtual acupressure can prevent the joint pain that often causes Black women to stop taking their breast cancer hormone therapy. About 150 Non-Hispanic Black postmenopausal women with early-stage breast cancer will be enrolled. Th…

This study is tracking 100 people with HER2-negative metastatic breast cancer who are receiving antibody-drug conjugates (ADCs) as part of their normal care. Researchers want to see how long these drugs control the cancer in real-world settings. The goal is to gather information …